The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Co-distribution agreement with Elemental Machines

11 Mar 2021 07:00

RNS Number : 8628R
DeepMatter Group PLC
11 March 2021
 

11 March 2021

 

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

 

DeepMatter signs co-distribution agreement with Elemental Machines

Providing expanded marketing footprint in the US

 

DeepMatter Group plc, the AIM-quoted company focusing on digitising chemistry, is pleased to announce it has signed a co-distribution agreement with Elemental Machines, the US based organisation helping biotechnology and pharmaceutical companies identify research problems through its sensor-based products.

 

This agreement will see Elemental Machines promote DeepMatter's integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware®, to its wide network of small and mid-size biotech North American customers through its sales team, presenting the Group with the opportunity to broaden its customer base and help establish sales opportunities across North America with organisations in the pharmaceutical and biotechnology sectors. DeepMatter will promote Elemental Machines' sensor-based products to its established European network who are interested in a wider sphere of real-time digital inputs for monitoring their laboratory environment, thereby expanding the number of laboratory devices which can integrate with the DigitalGlassware® platform.

 

Founded in 2015 by serial entrepreneur Sridhar Iyengar, Elemental Machines aims to enable reproducibility among the life sciences by using sensory equipment to gather and assess critical variables in the laboratory that can influence the result of an experiment. Their platform empowers LabOps Professionals to proactively run their labs. It currently works with over 200 customers, primarily in North America.

 

Mark Warne, CEO of DeepMatter, commented: "Elemental Machines is an organisation which shares our values of innovation and the pursuit of scientific discovery, and we're pleased to be advancing these with this collaboration. Importantly, this co-distribution agreement provides us with the capability to cast a wider net in North America, and we are very much looking forward to working with Elemental Machines as we capitalise upon this opportunity."

 

Sridhar Iyengar, CEO of Elemental Machines said: "Like Elemental Machines, DeepMatter is another organisation which recognises the enormous potential for the digitisation of chemistry. We believe that DigitalGlassware® is the most effective tool in the market for solving the reproducibility problem and the product offering will resonate well with our customer base.

 

"With both our customers set to benefit from the additional offerings we can now present, I look forward to seeing the difference we can make together in building labs fit for the future."

 

 

For more information, please contact:

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

 

 

 

 

Canaccord Genuity Limited (Nominated Advisor and Broker)

 

T: 020 7523 8000

Bobbie Hilliam / Angelos Vlatakis

 

 

Alma PR

T: 020 3405 0205

Caroline Forde / Harriet Jackson / Kieran Breheny / Faye Calow

deepmatter@almapr.co.uk

 

 

About DeepMatter Group plc 

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. It has developed and is commercialising data rich platform technologies, including software and laboratory hardware, focused on applications to improve R&D productivity and discovery using Machine Learning / Artificial Intelligence. 

 

DeepMatter's technologies allow chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. They are designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster. 

 

Visit: www.deepmatter.io and follow @deepmattergroup

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAXDEFDLFEFA
Date   Source Headline
22nd Mar 201910:39 amRNSHolding(s) in Company
20th Mar 20197:00 amRNSDirectors' Shareholdings
19th Mar 20194:52 pmRNSReplacement - Total Voting Rights and Notice of...
19th Mar 20193:35 pmRNSHolding(s) in Company
19th Mar 20193:32 pmRNSHolding(s) in Company
15th Mar 20198:10 amRNSTotal Voting Rights and Notice of Results
12th Mar 20197:00 amRNSGrant of Options
11th Mar 201912:58 pmRNSResult of Meeting & Directorate Change
7th Mar 20199:00 amRNSIssue of Equity
25th Feb 20197:00 amRNSAcquisition, Placing & Waiver of Rule 9
14th Feb 20193:58 pmRNSHolding(s) in Company
6th Feb 20194:42 pmRNSHolding(s) in Company
6th Feb 20194:41 pmRNSHolding(s) in Company
17th Jan 20197:00 amRNSDisposal of SICM business
20th Dec 20187:00 amRNSUpdate, Conditional Acquisition & Proposed Placing
30th Nov 20187:00 amRNSPublication of Paper in leading Journal
6th Sep 20183:06 pmRNSExercise of Options and Issue of Equity
6th Sep 20187:00 amRNSInterim Results
15th Aug 20187:00 amRNSFurther Pioneer Agreements and Notice of Results
19th Jul 20187:00 amRNSPublication of Scientific Paper
11th Jun 20187:00 amRNSDirectorate Changes
11th Jun 20187:00 amRNSIssue of Equity
16th May 201811:45 amRNSResult of AGM, name change and new website
24th Apr 20187:00 amRNSDirector Dealing
19th Apr 20187:00 amRNSSecond Pioneer Agreement Signed
12th Apr 20187:00 amRNSFirst Pioneer Agreement Signed
5th Apr 20183:28 pmRNSDirector Dealing
28th Mar 20187:00 amRNSFinal results for the year ended 31 December 2017
6th Feb 20187:00 amRNSMoUs signed with pioneers
19th Jan 20189:00 amRNSPublication of Scientific Paper
17th Jan 20187:00 amRNSPublication of Scientific Paper
6th Dec 20177:00 amRNSDirector Dealing
4th Dec 20177:00 amRNSNew Share Option Scheme and Grant to PDMR
1st Dec 20171:01 pmRNSDirectors' Dealing
28th Nov 20179:47 amRNSDirector Dealing
22nd Nov 20175:50 pmRNSHolding(s) in Company
20th Nov 201711:02 amRNSHolding(s) in Company
8th Nov 20178:11 amRNSCompletion of Acquisition, Appointment of Director
3rd Nov 20177:00 amRNSAcquisition of OpenIOLabs Limited
4th Oct 20177:00 amRNSChange of Adviser
12th Sep 20177:00 amRNSHalf-year Report
19th May 201711:34 amRNSResult of AGM
26th Apr 20177:00 amRNSDirectorate Changes
28th Mar 20177:00 amRNSFinal Results
16th Feb 20177:00 amRNSDigital Chemistry to be performed in space
31st Jan 20178:03 amRNSAdvisory Committee
31st Jan 20177:00 amRNSPresentation at Healthcare Conference
9th Jan 20177:00 amRNSDigitalGlasswareT
15th Sep 20167:00 amRNSHalf-year Report
12th May 201611:45 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.